Ole Thastrup
Founder at 2CUREX AB
Ole Thastrup active positions
| Companies | Position | Start | End |
|---|---|---|---|
| 2CUREX AB | Director/Board Member | 01/01/2006 | - |
| Founder | 01/01/2006 | - | |
| Chief Executive Officer | 01/01/2006 | 01/02/2021 | |
| Chief Tech/Sci/R&D Officer | 01/02/2021 | 01/01/2024 | |
| Investor Relations Contact | 01/01/2006 | 01/01/2024 | |
2cureX ApS
 2cureX ApS Pharmaceuticals: MajorHealth Technology 2cureX ApS develops and manufactures drugs and technology for the treatment of cancer. Its ChemoCellomics, integrates synthesis of compound libraries with throughput screening (HTS) in primary cells from patients. The company was founded by Ole Thastrup, Timm Jessen, and Grith Hagel in 2006 and is headquartered in Birkerod, Denmark. | Director/Board Member | 01/01/2006 | - |
| Chief Tech/Sci/R&D Officer | 01/01/2006 | - | |
| Founder | 01/01/2006 | - | |
| University of Copenhagen | Corporate Officer/Principal | - | - |
| Ot311 ApS | Director/Board Member | - | - |
| Chief Executive Officer | - | - | |
Novo Nordisk Fonden
 Novo Nordisk Fonden Investment Trusts/Mutual FundsMiscellaneous Novo Nordisk Fonden provides basis for the commercial and research activities conducted by the companies. It also supports scientific and humanitarian purposes activities. It awards grants for research within biomedicine, biotechnology, general practice and family medicine, nursing, and art history at public research institutions. It bridges gap between the discoveries made by researchers in biomedicine and biotechnology and their commercial application. The company was founded by August Krogh, Marie Krogh, Harald Pedersen, Hans Christian Hagedorn, August Kongsted and Thorvald Pedersen in 1922 and is headquartered in Hellerup, Denmark. | Corporate Officer/Principal | - | - |
Career history of Ole Thastrup
Former positions of Ole Thastrup
| Companies | Position | Start | End |
|---|---|---|---|
| CARLSBERG A/S | Corporate Officer/Principal | 01/01/2002 | 01/01/2006 |
| Noapab Holdings A/S | Chief Tech/Sci/R&D Officer | - | - |
ZymoGenetics, Inc.
 ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Corporate Officer/Principal | - | - |
| NOVO NORDISK A/S | Corporate Officer/Principal | - | - |
Statistics
International
| Denmark | 9 |
| United States | 2 |
Operational
| Corporate Officer/Principal | 5 |
| Director/Board Member | 3 |
| Chief Tech/Sci/R&D Officer | 3 |
Sectoral
| Health Technology | 5 |
| Consumer Non-Durables | 2 |
| Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 3 |
|---|---|
| CARLSBERG A/S | Consumer Non-Durables |
| NOVO NORDISK A/S | Health Technology |
| 2CUREX AB | Health Technology |
| Private companies | 5 |
|---|---|
2cureX ApS
2cureX ApS Pharmaceuticals: MajorHealth Technology 2cureX ApS develops and manufactures drugs and technology for the treatment of cancer. Its ChemoCellomics, integrates synthesis of compound libraries with throughput screening (HTS) in primary cells from patients. The company was founded by Ole Thastrup, Timm Jessen, and Grith Hagel in 2006 and is headquartered in Birkerod, Denmark. | Health Technology |
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Health Technology |
| Noapab Holdings A/S | Commercial Services |
| Ot311 ApS | |
Novo Nordisk Fonden
Novo Nordisk Fonden Investment Trusts/Mutual FundsMiscellaneous Novo Nordisk Fonden provides basis for the commercial and research activities conducted by the companies. It also supports scientific and humanitarian purposes activities. It awards grants for research within biomedicine, biotechnology, general practice and family medicine, nursing, and art history at public research institutions. It bridges gap between the discoveries made by researchers in biomedicine and biotechnology and their commercial application. The company was founded by August Krogh, Marie Krogh, Harald Pedersen, Hans Christian Hagedorn, August Kongsted and Thorvald Pedersen in 1922 and is headquartered in Hellerup, Denmark. | Miscellaneous |
- Stock Market
- Insiders
- Ole Thastrup
- Experience